Zhongguancun: Subsidiary's Bisoprolol Amlodipine Tablets Obtain Drug Registration Certificate

Zhongguancun announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. received the Drug Registration Certificate approved and issued by the National Medical Products Administration, and its developed Bisoprolol Amlodipine Tablets passed the drug registration review and approval, with a registration classification of Class 4 chemical drugs and a drug validity period of 18 months. As of August 31, 2026, the project had accumulated R&D investment of 9.3737 million yuan. The drug is a hypertension treatment medication, and its approval will enrich the company's product line; there is uncertainty regarding its future production and sales.